Portal de Periódicos da CAPES

90 Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

2015; National Academy of Sciences; Volume: 112; Issue: 42 Linguagem: Inglês

10.1073/pnas.1516107112

1091-6490

John E. Janik, John C. Morris, Deirdre O’Mahony, Stefania Pittaluga, Elaine S. Jaffe, Christophe E. Redon, William M. Bonner, Martin W. Brechbiel, Chang H. Paik, Millie Whatley, Clara Chen, Jae Ho Lee, Thomas A. Fleisher, M. D. Brown, Jeffrey D. White, Donn M. Stewart, Suzanne Fioravanti, Cathryn C. Lee, Carolyn K. Goldman, Bonita R. Bryant, Richard P. Junghans, Jorge A. Carrasquillo, Tatyana Worthy, Erin M. Corcoran, Kevin C. Conlon, Thomas A. Waldmann,

Monoclonal and Polyclonal Antibodies Research

Significance Despite advances, a significant proportion of patients with Hodgkin’s lymphoma (HL) will not respond or will relapse. We demonstrated that up to seven infusions of 90 Y-daclizumab, an anti-CD25–directed monoclonal antibody, provided responses in 50% of patients with relapsed HL. The daclizumab was directed primarily not at tumor cells themselves but toward nonmalignant T cells rosetting around the Reed–Sternberg cells. 90 Y provided strong β emissions that killed antigen-nonexpressing tumor cells at a distance by a crossfire effect. Furthermore, the strong β irradiation killed normal cells in the tumor microenvironment that nurture the malignant cells in the lymphomatous mass. Therefore 90 Y-daclizumab infusions provide meaningful therapy for select HL patients.